SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences inks pact with CVS Caremark

07 Jan 2025 Evaluate

Zydus Lifesciences has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet XR (Sitagliptin / Sitagliptin and Metformin Hydrochloride) tablets to its template formulary. CVS Caremark will add the company’s Zituvio and combination products to its template formulary starting January 1, 2025. 

Zituvio and combination products include Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the United States Food and Drug Administration (USFDA) earlier through the 505(b)(2) route. The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

According to IQVIA (MAT August-2023), U.S. market for DPP-IV inhibitors and their combinations is $10 billion.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×